Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$55.92 USD

55.92
2,846,383

+0.12 (0.22%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $55.90 -0.02 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Catalent (CTLT) Down 6.5% Since Last Earnings Report: Can It Rebound?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

Compared to Estimates, Catalent (CTLT) Q4 Earnings: A Look at Key Metrics

The headline numbers for Catalent (CTLT) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Catalent (CTLT) Gains Post Deal With Elliott and Earnings Report

Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and its strategic investments.

Catalent (CTLT) Preliminary Q4 Revenues Dampened by Lower Sales

Catalent (CTLT) records lower revenues in Biologics segment in its fourth-quarter fiscal 2023, resulting in overall soft preliminary performance.

Catalent (CTLT) Q4 Earnings Miss Estimates

Catalent (CTLT) delivered earnings and revenue surprises of -10% and 1.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) to Report Q4 Earnings: What's in the Cards?

Catalent's (CTLT) Q4 results are likely to be affected by soft segmental performances.

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 22.64% and 216.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Misses Revenue Estimates

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 2.56% and 88.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Catalent (CTLT) Up 3.5% Since Last Earnings Report: Can It Continue?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL

Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.

Catalent (CTLT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Catalent (CTLT) Tops Q3 Earnings Estimates, Cuts FY23 View

Catalent (CTLT) records lower revenues in both segments in third-quarter fiscal 2023, resulting in overall soft performance.

Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates

Catalent (CTLT) delivered earnings and revenue surprises of 30.77% and 11.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Launches Expanded OneBio Suite to Aid Customers

Catalent's (CTLT) expansion of its OneBio Suite across multiple biologic therapies is expected to aid customers in leveraging its end-to-end capabilities in these areas.

Catalent (CTLT) Expands Its Facility Capabilities in Shiga

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -22.22% and 28.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 0% and 23.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.